KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.73
-0.04 (-4.82%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.90M | 3.72M | 4.29M |
| Net Income | 467.4K | 601.6K | 528.1K |
| EPS | — | — | — |
| Profit Margin | 12.0% | 16.2% | 12.3% |
| Rev Growth | +18.2% | +4.0% | +10.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 6.27M | 6.55M | 6.27M |
| Total Equity | 7.03M | 8.06M | 8.15M |
| D/E Ratio | 0.89 | 0.81 | 0.77 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.16M | 1.10M | 1.24M |
| Free Cash Flow | 801.3K | 617.9K | 781.1K |